Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
ClearBridge Investments’ first quarter 2026 commentary highlighted ICON (NasdaqGS:ICLR) after the fund exited its position, citing investor concerns that AI could disrupt traditional drug development workflows and weigh on contract research organizations.
See our latest analysis for ICON.
At a share price of $113.06, ICON has seen a 14.98% 1 month share price return and a 5.51% 7 day share price return. However, this follows a 40.08% year to date share price decline and a 22.12% 1 year total shareholder return decline, suggesting recent momentum comes after a much weaker longer term trend as investors reassess AI related risks to contract research models.
If concerns around AI disruption have you reassessing healthcare exposure, it could be a useful moment to see what else is on the move through 34 healthcare AI stocks.
With ICON trading at $113.06, a 49% modelled intrinsic discount and a 17% gap to the average analyst target raise an obvious question: is this a mispriced AI worry, or is the market already discounting future growth?
ICON’s most followed narrative pegs fair value at $142.86 versus the current $113.06, putting the model’s discount assumptions firmly in the spotlight.
The updated analyst price target for ICON moves lower to $142.86 from $154.86, with analysts citing accounting-related uncertainty and potential backlog restatements, partially balanced by views that the recent selloff and current valuation may offer a more compelling risk and reward profile.
Want to see what sits behind that cut to fair value? The narrative leans on measured revenue growth, tighter profit assumptions and a reset earnings multiple. Curious which inputs matter most and how they tie into that $142.86 figure? The full story is in the detailed forecast path, not just the headline discount.
Result: Fair Value of $142.86 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, you still need to keep an eye on the accounting review and any backlog restatements, as these could shift earnings expectations and investor confidence quickly.
Find out about the key risks to this ICON narrative.
With both risks and rewards on the table, does the current sentiment around ICON reflect the full picture or just the latest headlines? Take a closer look at the details and form your own view by weighing its 3 key rewards and 2 important warning signs.